Radiometallation of receptor-specific peptides for diagnosis and treatment of human cancer

In Vivo

Volumn 19, Issue 1, 2005, Pages 9-30

  Giblin, Michael F ^a,b   Veerendra, Bhadrasetty ^b   Smith, Charles J ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b University of Missouri   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

Author keywords

Bombesin; Diagnosis; Peptides; Radionuclide; Review; Somatostatin; Therapy

Indexed keywords

ASTATINE 211; BISMUTH; BISMUTH 212; CADMIUM DERIVATIVE; COPPER 64; GALLIUM 67; GALLIUM 68; HOLMIUM; HOLMIUM 166; INDIUM; INDIUM 111; LUTETIUM; LUTETIUM 177; MOLYBDENUM; PENTETREOTIDE; PENTETREOTIDE IN 111; PEPTIDE DERIVATIVE; PROMETHIUM; PROMETHIUM 149; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; RHENIUM 188; RHODIUM; RHODIUM 105; SAMARIUM 153; TECHNETIUM 99M; UNCLASSIFIED DRUG; UNINDEXED DRUG; YTTRIUM; YTTRIUM 86; YTTRIUM 90;

ADENOCARCINOMA; ALPHA RADIATION; BETA RADIATION; BIOTECHNOLOGY; BREAST CANCER; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER THERAPY; CARCINOID; CHELATION; CLINICAL PROTOCOL; CYCLOTRON; DRUG CONJUGATION; DRUG DESIGN; DRUG HALF LIFE; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; GAMMA SCINTIGRAPHY; GENE OVEREXPRESSION; GENERATOR; HUMAN; IN VIVO STUDY; INTESTINE CARCINOMA; IONIZING RADIATION; ISOTOPE LABELING; NEUROENDOCRINE TUMOR; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN FUNCTION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 16244378596     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (186)

1. Eary JF, Schroff RW, Abrams PG, Fritzberg AR, Morgan AC, Kasina S, Reno JM, Srinivasan A, Woodhouse CS and Wilbur DS: Successful imaging of malignant melanoma with technetium-99m-labeled monoclonal antibodies. J Nucl Med 30: 25-32, 1989.
2. Fritzberg AR and Wilbur DS: Radiolabeling of antibodies for targeted diagnostics. In: Targeted Delivery of Imaging Agents. Boca Raton, FL, CRC Press, Inc., 1995, pp 83-101.
3. Goldenberg DM and Larson SM: Radioimmunodetection in cancer identification. J Nucl Med 33: 803-814, 1992.
4. Press OW, Appelbaum FR, Early JF and Bernstein ID: Radiolabeled antibody therapy of lymphomas. Biolog Ther Cancer Update 4: 1-13, 1994.
5. Jain RK: Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst 81: 570-576, 1989.
6. 111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci 49: 1583-1591, 1991.
7. Eckelman, WC and Gibson RE: The design of site-directed radiopharmaceuticals for use in drug discovery. In: Nuclear Imaging in Drug Discovery, Development, and Approval (Burns HD, Gibson RE, Dannals R and Siegl P, eds), Boston, Birkhauser, 1993, pp 113-134.
8. Fischman AJ, Babich JW and Strauss HW: A ticket to ride: peptide radiopharmaceuticals. J Nucl Med 34: 2253-2263, 1993.
9. Nagy A, Szoke B and Schally AV: Selective coupling of methotrexate to peptide hormone carriers through a gamma-carboxamide linkage of its glutamic acid moiety: benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate activation in salt coupling. Proc Natl Acad Sci USA 90: 6373-6376, 1993.
10. Reubi JC: Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med 36: 1825-1835, 1995.
11. Larson S: Receptors on tumors studied with radionuclide scintigraphy. J Nucl Med 32: 1189-1191, 1991.
12. Pinski J, Reile H, Halmos G, Groot K and Schally AV: Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Int J Cancer 59: 51-55, 1994.
13. Reubi JC: In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. J Nucl Med 36: 1846-1853, 1995.
14. Stokkel MP and Pauwels EK: Octreotide scintigraphy for small cell lung carcinoma: past, present or future? Eur J Nucl Med 21: 1276-1278, 1994.
15. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20: 716-731, 1993.
16. Liu S and Edwards DS: Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconjugate Chem 12: 7-34, 2001.
17. Giblin MF, Wang N, Hoffman TJ, Jurisson SS and Quinn TP: Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc Natl Acad Sci USA 95: 12814-12818, 1998.
18. 105Rh(III) complexes with macrocycles. J Labelled Compd Radiopharm 37: 426-428, 1995.
19. 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. J Med Chem 42: 1341-1347, 1999.
20. Stolz B, Smith-Jones PM, Weckbecker G, Albert R, Knecht H, Haller R, Tolcsvai L, Hofman G, Pollehn K and Bruns C: Radiotherapy with yttrium-90 labeled DOTA-Tyr3-octreotide in tumor bearing rodents. J Nucl Med 38: 18, 1997.
21. Blok D, Feitsma RI, Vermeij P and Pauwels EJ: Peptide radiopharmaceuticals in nuclear medicine. Eur J Nucl Med 26: 1511-1519, 1999.
22. Boerman OC, Oyen WJG and Corstens FHM: Radio-labeled receptor-binding peptides: a new class of radiopharmaceuticals. Sern Nucl Med 30: 195-208, 2000.
23. 99mTc-labelled peptide-based radiopharmaceuticals: an overview. Nuclear Med Commun 20 1093-1112, 1999.
24. Schally AV, Comaru-Schally AM, Plonowski A, Nagy A, Halmos G and Rekasi Z: Peptide analogs in the therapy of prostate cancer. Prostate 45: 158-166, 2000.
25. 99mTc-labeled peptides. J Nucl Med 41: 177-182, 2000.
26. Kwekkeboom D, Krenning EP and de Jong M: Peptide receptor imaging and therapy. J Nucl Med 41: 1704-1713, 2000.
27. Anderson CJ and Welch MJ: Radiometal-labeled agents (non-technetium) for diagnostic imaging. Chem Rev 99: 2219-2234, 1999.
28. Jurisson S, Berning D, Jia W and Ma D: Coordination compounds in nuclear medicine. Chem Rev 93: 1137-1156, 1993.
29. Jurisson S and Lydon JD: Potential technetium small molecule radiopharmaceuticals. Chem Rev 99: 2205-2218, 1999.
30. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev 99: 2235-2268, 1999.
31. Chart of the Nuclides, Fifteenth Edition. Copyright©1996, General Electric Co. and KAPL Inc..
32. Pearson RG: Hard and soft acids and bases. J Am Chem Soc 22: 3533-3539, 1963.
33. Martell AE and Hancock RD: Metal Complexes in Aqueous Solutions. New York Plenum, 1996.
34. 66Ga as a positron emitting label of albumin colloids for clinical use. Eur J Nucl Med 14 152, 1988.
35. 66Ga. J Nucl Med 38: 200, 1997.
36. Herzog H, Rosch F, Stocklin G, Lueders C, Qaim SM and Feinendegen LE: Measurement of pharmacokinetics of yttrium-86 radiopharmaceuticals with PET and radiation dose calculation of analogous yttrium-90 radiotherapeutics. J Nucl Med 34: 2222, 1993.
37. 90Y-DOTA-Tyr3-OCTREOTIDE as measured in baboons by means of Yttrium-86 and PET. J Nucl Med 38: 60, 1997.
38. Volkert WA and Hoffman TJ: Therapeutic radiopharmaceuticals. Chem Rev 99: 2269-2292, 1999.
39. Fritzberg AR, Gustavson LM, Hylarides MD and Reno JM: Chemical and structural approaches to rational drug design. In: Weiner DB, Williams MV, eds. Boca Raton, FL, CRC Press, p 125, 1995.
40. Schubiger PA, Alberto R and Smith A: Vehicles, chelators, and radionuclides: choosing the "building blocks" of an effective therapeutic radioimmunoconjugate. Bioconjugate Chem 7: 165-179, 1996.
41. Volkert WA, Goeckeler WF, Ehrhardt GJ and Ketring AR: Therapeutic radionuclides: production and decay property considerations. J Nucl Med 32: 174-185, 1991.
42. Ehrhardt GJ, Ketring AR and Ayers LM: Reactor-produced radionuclides at the University of Missouri Research Reactor. Appl Radiat Isot 49: 295-297, 1998.
43. Cutler CS, Smith CJ, Ehrhardt GJ, Tyler TT, Jurisson SS and Deutsch E: Current and potential therapeutic uses of Lanthanide radioisotopes. Cancer Biotherap Radiopharmaceut 15(6): 531-545, 2000.
44. Eckelman WC: Radiolabeling with technetium-99m to study high-capacity and low-capacity biochemical systems. Eur J Nucl Med 22 249, 1995.
45. Smith CJ, Volkert WA and Hoffman TJ: Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update. Nucl Med Biol 30: 861-868, 2002.
46. 2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies. Anticancer Res 23: 63-70, 2003.
47. Pillai MRA, Lo JM and Troutner DE: Labeling of hematoporphyrin with Rhodium-105 and binding studies with human gamma globulin. Appl Radiat Isot 41: 69-73, 1990.
48. 105Rh complex of tetrathiacyclohexadecane diol with potential for formulating bifunctional chelates. Nucl Med Biol 23: 33, 1996.
49. Goswami M, Alberto R, Barnes CL and Jurisson S: Rhodium (III) complexes with acyclic tetrathioether ligands. Effects of backbone chain length on the conjugation of the Rh (III)complex. Inorg Chem 35: 7546-755, 1996.
50. 2: a new gastrin releasing peptide receptor (GRPr) targeting radiopharmaceutical. J Labelled Compd Radiopharm 44: 706-708, 2001.
51. Howell RW, Azure MT, Narra VR and Rao DV: Relative biological effectiveness of alpha-particle emitters in vivo at low doses. Radiat Res 137: 352-360, 1994.
52. Kozak RW, Atcher RW, Gansow OA, Friedman AM, Hines JJ and Waldman TA: Bismuth-212-labeled anti-TAC monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radiommumotherapy. Proc Natl Acad Sci USA 83 (2): 474-478, 1986.
53. Zalutsky MR and Bigner DD: Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. Acta Oncol 35: 373-379, 1996.
54. Kassis AI, Harris CR, Adelstein SJ, Ruth TJ, Lambrecht R and Wolf AP: The in vitro radiobiology of astatine-211 decay. Radiat Res 105(1): 27-36, 1986.
55. 213Bi. Nucl Med Biol 26 149-157, 1999.
56. 99mTc-labelled peptide-based radiopharmaceuticals. Nucl Med Commun 20: 1093-1112, 1999.
57. 99mTc. Nucl Med Biol 18: 667-676, 1991.
58. 188Re labeled antibodies. Appl Radiat Isot 47: 7-14, 1996.
59. John E, Thakur ML, DeFulvio J, McDevitt MR and Damjanov I: Rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: preparation and evaluation. J Nucl Med 34: 260-267, 1993.
60. 99mTc-pertechnetate at pH 7.4. Int J Appl Radiat Isot 29: 251-253, 1978.
61. Hnatowich DJ: Antibody radiolabeling, problems and promises. Nucl Med Biol 17: 49-55, 1990.
62. Sundberg MW, Meares CF, Goodwin DA and Diamanti CI: Selective binding of metal ions to macromolecules using bifunctional analogs of EDTA. J Med Chem 17: 1304, 1974.
63. 99mTc. Int J Nucl Med Biol 12: 3, 1985.
64. Maina T, Stolz B, Albert R, Bruns C, Koch P and Macke H: Synthesis, radiochemistry and biological evaluation of a new somatostatin analogue(SDZ 219-387) labeled with technetium-99m. Eur J Nucl Med 21 437, 1994.
65. 99mTc] chelator-peptide conjugates. Bioconj Chem 7: 196, 1996.
66. Rao TN, Adhikesavalu D, Camerman A and Fritzberg AR: Technetium (V) and rhenium (V) complexes of 2,3-bis (mercaptoacetamido)propanoate. Chelate ring stereochemistry and influence on chemical and biological properties. J Am Chem Soc 112: 5798, 1990.
67. Eshima D, Taylor A, Fritzberg AR, Kasina S, Hansen L and Sorenson JF: Animal evaluation of technetium-99m triamide mercaptide complexes as potential renal imaging agents. J Nucl Med 28: 1180, 1987.
68. Subhani M, Cleynhens B, Bormans G, Hoogmartens M, DeRoo M and Verbruggen AM: Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine (Nicolini M, Banoli G and Ulderico M, eds.). Verona, Cortina International, 1989, Vol. 3, pp 453-461.
69. 99mTc-labelled agents. Nucl Med Biol 22: 325 1996.
70. Jurisson S, Schlemper EO, Troutner DE, Canning LR, Nowotnik DP and Neirinckx RD: Synthesis, characterization, and x-ray structural determinations of technetium(V)-oxo-tetradentate amine oxime complexes. Inorg Chem 25(4): 543-549, 1986.
71. 2. Inorg Chem 26: 3576, 1987.
72. Van de Wiele C, Dumont F, Broecke RV, Oosterlinck W, Cocquyt V, Serreyn R, Peers S, Thornback J, Slegers G and Dierckx RA: Technetium-99m RP527, a GRP analogue for visualization of GRP receptor-expressing malignancies: a feasible study. Eur J Nucl Med 27 1694-1699, 2000.
73. 2: an in vitro/in vivo structure-activity relationship study where X = 0-, 3-, 5-, 8-, and 11-carbon tethering moieties. Bioconj Chem 14: 93-102, 2003.
74. Abrams MJ, Juweid M, tenKate CI, Schwartz DA, Hauser MM, Gaul FE, Fuccello AJ, Rubin RH, Strauss W and Fischman AJ: Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med 31: 2022-2028, 1990.
75. 99mTc-labeled HYNIC-derivatized annexin V for human use. Nucl Med Biol 30: 771-778, 2003.
76. 99mTc-labeled hydrazino nicotinic acid derivatized chemotactic peptides. Nucl Med Biol 22: 25-30, 1995.
77. Decristoforo C and Mather SJ: Technetium-99m somatostatin analogues: effect of labelling methods and peptide sequence. Eur J Nucl Med 26: 869-876, 1999.
78. Hnatowich DJ, Winnard Jr P, Virzi F, Fogarsi M, Sano T, Smith CL, Cantor CL and Rusckowski M: Technetium-99m labeling of DNA. J Nucl Med 36: 2306-2314, 1995.
79. 99mTc-labeled interleukin-8 in detection of infection. Bioconj Chem 13(2): 370-377, 2002.
80. 99mTc-HYNIC-folate: A novel receptor-based targeted radiopharmaceutical for tumor imaging. J Nucl Med 40: 1563-1569, 1999.
81. 99mTc-technetium-labelled peptide-HYNIC conjugates: effects of lipophilicity and stability on biodistribution. Nucl Med Biol 26: 389-396, 1999.
82. Fichna J and Janecka A: Synthesis of target-specific radiolabeled peptides for diagnostic imaging. Bioconj Chem 14: 3-17, 2003.
83. 99mTc using aminocarboxylates as coligands. Bioconj Chem 7: 63-71, 1996.
84. 99mTc-labeling of hydrazino nicotinamide-modified biologically active molecules using imine-N-containing heterocycles as coligands. Bioconj Chem 9: 583-595, 1998.
85. 99mTc-labeling of highly potent small peptides. Bioconj Chem 8: 621-636, 1997.
86. Zalutsky MR and Narula AS: Radiohalogenation of a monoclonal antibody using an N-succinimidyl 3-(tri-n-butylstannyl) benzoate intermediate. Cancer Res 48: 1446-1450, 1988.
87. +. In: Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine (Nicolini M, and Ulderico M, eds.), SGE, Italy, 1999, pp27-34.
88. + (M = Re, Tc) directed towards radiopharmaceutical application. Coord Chem Rev 190-192, 901-919, 1999.
89. + and synthesis of tailor-made bifunctional ligand systems. Bioconj Chem 13: 750-756, 2002.
90. - in aqueous solution and its reaction with a bifunctional ligand. J Am Chem Soc 120: 7987-7988, 1998.
91. 99mTc-aquaion labels peptide to an unprecedented high specific activity. J Nucl Med 40(11): 1913-1917, 1999.
92. 3]2-. Synthesis, characterization, and structures of rhenium(I) tricarbonyl complexes with thiourea and thiourea derivatives. Inorg Chem Acta 248: 193-202, 1996.
93. +-Core. Nucl Med Biol 26: 711-716, 1999.
94. + labels peptide to an unprecedented high specific activity. A labeling study with amino acids and neurotensin. In: Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine (Nicolini M and Ulderico M, eds.), SGE, Italy, 1999, pp507-512.
95. Roselli M, Schlom J, Gansow OA, Brechbiel MW, Mirzadeh S, Pipppin CG, Milenic EE and Colcher D: Comparative biodistribution studies of DTPA-derivative bifunctional chelates for radiometal labeled monoclonal antibodies. Int J Rad Appl Instrum B 18: 389-394, 1991.
96. Cummins CH, Rutter EW Jr and Fordyce WA: A convenient synthesis of bifunctional chelating agents based on diethylenetriaminepentaacetic acid and their coordination chemistry with yttrium (III). Bioconj Chem 2: 18-186, 1991.
97. 0]octreotide in patients. Eur J Nucl Med 28: 1319-1325, 2001.
98. 177Lu-DOTA-Y3-Octreotate in a rat model. Int J Cancer 94: 873-877, 2001.
99. 90Y-DOTA-D-Phe1- Tyr3-octreotide: preliminary report in cancer patients. Cancer Biother Radiopharm 14: 477-483, 1999.
100. 2 conjugate for specific targeting of tumors expressing gastrin releasing peptide receptors (GRP-R). J Nucl Med (Supplement) 41(5): 119P, 2000.
101. 2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells. Nucl Med Biol 30: 101-109, 2002.
102. Hoffman TJ, Quinn TP and Volkert WA: Radiometallated receptor-avid peptide conjugates for specific in vivo targeting of cancer cells. Nucl Med Biol 28: 527-539, 2001.
103. 105Rh(III) complexes with macrocycles. J Labelled Compd Radiopharm 37: 426-428, 1995.
104. 105Rh labeled bombesin analogues: enhancement of GRP receptor binding affinity utilizing aliphatic carbon chain linkers. J Labelled Compd Radiopharm 40: 490-493, 1997.
105. 99mTc-labeled peptides. Q J Nucl Med 46: 195-205, 2002.
106. Reubi JC: Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocrine Rev 24: 389-427, 2003.
107. Gotthardt M, Boermann OC, Behr TM, Behe MP and Oyen WJG: Development and clinical application of peptide-based radiopharmaceuticals. Curr Pharm Des 10: 2951-2963, 2004.
108. Britz-Cunningham SH and Adelstein SJ: Molecular targeting with radionuclides: state of the science. J Nucl Med 44: 1945-1961, 2003.
109. Krenning EP, Kwekkeboom DJ, Valkema R, Pauwels S, Kvols LK and de Jong M: Peptide receptor radionuclide therapy. Ann NY Acad Sci 1014: 234-245, 2004.
110. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D and Bruns C: Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nature Rev Drug Disc 2: 999-1017, 2003.
111. Froidevaux S and Eberle AN: Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers 66: 161-183, 2002.
112. Krenning EP, Bakker WH, Breeman WAP, Koper JW, Kooij PPM, Ausema L, Lameris JS, Reubi JC and Lamberts SWJ: Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1: 242-244, 1989.
113. 111In-pentetreotide scintigraphy. J Nucl Med 43: 889-895, 2002.
114. Virgolini I, Traub T, Novotny C, Leimer M, Fuger B, Li SR, Patri P, Panger T, Angelberger P, Raderer M, Burggasser G, Andreae F, Kurtaran A and Dudczak R: Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr Pharm Des 8: 1781-1807, 2002.
115. Virgolini I, Szilvasi I, Kurtaran A, Angelberger P, Raderer M, Havlik E, Vorbeck F, Bischof C, Leimer M, Dorner G, Kletter K, Niederle B, Scheithauer W and Smith-Jones P: Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients. J Nucl Med 39: 1928-1936, 1998.
116. Otte A, Harrmann R, Heppeler A, Behe M, Jermann E, Powell P, Maecke HR and Muller J: Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 26: 1439-1447, 1999.
117. 90Y-labelled analogue. Eur J Nucl Med 26: 358-366, 1999.
118. 68Ga-DOTATOC: preliminary data. Eur J Nucl Med 28: 1751-1757, 2001.
119. 111In-DTPA-octreotide. Eur J Nucl Med 28: 1743-1750, 2001.
120. 64CU-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med 42 213-221, 2001.
121. Boerman OC, Oyen WJG and Corstens FHM: Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney. Eur J Nucl Med 28: 1447-1449, 2001.
122. Wild D, Schmitt JS, Ginj M, Maecke HR, Bernard BF, Krenning E, de Jong M, Wenger S and Reubi JC: DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 30: 1338-1347, 2003.
123. Anastasi A, Erspamer V and Nucci M: Isolation and amino acid sequences of alytesin and bombesin, two analogous active tetradecapeptides from the skin of european discoglossid frogs. Arch Biochem Biophys 148: 443-446, 1972.
124. Girard F, Bachelard H, St-Pierre S and Rioux F: The contractile effect of bombesin, gastrin releasing peptide and various fragments in the rat stomach strip. Eur J Pharmacol 102: 489-497, 1984.
125. Von Schrenck T, Heinz-Erian P, Moran T, Mantey SA, Gardner J and Jensen R: Neuromedin B receptor in esophagus: evidence for subtypes of bombesin receptors. Am J Physiol 256: G747-G758, 1989.
126. Spindel ER, Giladi E, Brehm P, Goodman RH and Segerson TP: Cloning and functional characterization of a complementary DNA encoding the murine fibroblast bombesin/gastrin releasing peptide receptor. Mol Endocrinol 4: 1956-1963, 1990.
127. Fathi Z, Corjay MH, Shapira H, Wada E, Benya R, Jensen R, Viallet J, Sausville EA and Battey JF: BRS-3: a novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells. J Biol Chem 268: 5979-5984, 1993.
128. 13]bombesin distinct from the receptor for gastrin releasing peptide: identification of a fourth bombesin receptor subtype (BB4). Proc Natl Acad Sci USA 92 6205-6209, 1995.
129. Van de Wiele C, Dumont F, Van Belle S, Slegers G, Peers SH and Dierckx RA: Is there a role for agonist gastrin-releasing peptide receptor radioligands in tumor imaging? Nucl Med Comm 22: 5-15, 2001.
130. Fischer JB and Schonbrunn A: The bombesin receptor is coupled to a guanine nucleotide-binding protein which is insensitive to pertussis and cholera toxins. J Biol Chem 263: 2808-2816, 1988.
131. Markwalder R and Reubi JC: Gastrin releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 59: 1152-1159, 1999.
132. Sun B, Halmos G, Schally AV, Wang X and Martinez M: Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. Prostate 42: 295-303, 2000.
133. Halmos G, Wittliff JL and Schally AV: Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Res 55: 280-287, 1995.
134. Gugger M and Reubi JC: Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol 155: 2067-2076, 1999.
135. Toi-Scott M, Jones CL and Kane MA: Clinical correlates of bombesin-like peptide receptor subtype expression in human lung cancer cells. Lung Cancer 15: 341-354, 1996.
136. Baidoo KE, Lin K-S, Zhan Y, Finley P, Scheffel U and Wagner HN: Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues. Bioconj Chem 9: 218-225, 1998.
137. 2: an in vitro/in vivo structure-activity relationship study where X = 0, 3, 5, 8, and 11-carbon tethering moieties. Bioconj Chem 14: 93-102, 2003.
138. 188Re of peptide conjugates containing a dithiabisphosphine chelating agent. Bioconj Chem 12: 354-363, 2001.
139. 64Cu-labeled bombesin analogue. Bioconj Chem 14: 756-763, 2003.
140. 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med 45: 1390-1397, 2004.
141. 99mTc]demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med Mol Imag 30: 247-258, 2003.
142. 3 selected from random phage display libraries. Biochemistry 34: 3948-3955, 1995.
143. 3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res 63: 2079-2087, 2003.
144. 3. Science 294: 339-345, 2001.
145. v integrin antagonists: novel anticancer agents. Exp Opin Invest Drugs 9: 1271-1279, 2000.
146. Sivolapenko GB, Skarlos D, Pectasides D, Stathopoulou E, Milonakis A, Sirmalis G, Stuttle A, Courtenay-Luck NS, Konstantinides K and Epenetos AA: Imaging of metastatic melanoma utilizing a technetium-99m labelled RGD-containing synthetic peptide. Eur J Nucl Med 25: 1383-1389, 1998.
147. 18F-labelled linear peptides. Eur J Nucl Med 29 754-759, 2002.
148. Pierschbacher MD and Ruoslahti E: Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion. J Biol Chem 262: 17294-17298, 1987.
149. Gottschalk K and Kessler H: The structures of integrins and integrin-ligand complexes: implications for drug design and signal transduction. Angew Chem Int Ed 41: 3767-3774, 2002.
150. Assa-Munt N, Jia X, Laakkonen P and Ruoslahti E: Solution structures and integrin binding activities of an RGD peptide with two isomers. Biochemistry 40: 2373-2378, 2001.
151. 3 integrin for tumor imaging. Bioconj Chem 13: 561-570, 2002.
152. Haubner R and Wester HJ: Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des 10: 1439-1455, 2004.
153. 3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med 40: 1061-1071, 1999.
154. Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, Kessler H and Schwaiger M: Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 42: 326-336, 2001.
155. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 61: 1781-1785, 2001.
156. 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imag 31: 1081-1089, 2004.
157. van Hagen PM, Breeman WAP, Bernard HF, Schaar M, Mooij CM, Srinivasan A, Schmidt, MA, Krenning EP and de Jong M: Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumor imaging and radionuclide therapy. Int J Cancer 90: 186-198, 2000.
158. 64Cu-labeled RGD peptide. Bioconj Chem 15: 41-49, 2004.
159. 3 integrin binding peptides in a nude mouse model. Cancer Res 62: 6146-6151, 2002.
160. 18F-labeled RGD and octreotide analogs. J Nucl Med 45: 892-902, 2004.
161. Dockray GJ: Vasoactive intestinal polypeptide and related peptides. In: Gut Peptides (Walsh JH and Dockray GJ, eds.) New York, Raven Press, 1994, pp 447-472.
162. 1 receptor agonist. J Biol Chem 275: 24003-24012, 2000.
163. Reubi JC, Laderach U, Waser B, Gebbers J, Robberecht P and Laissue JA: Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res 60: 3105-3112, 2000.
164. Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q, Li S, Banyai M, Pidlich J, Niederle B, Scheithauer W and Valent P: Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 33: 1116-1121, 1994.
165. Moody TW, Leyton J, Gozes I, Lang L and Eckelman WC: VIP and breast cancer. Ann NY Acad Sci 865: 290-296, 1998.
166. Virgolini I: Receptor nuclear medicine: vasointestinal peptide and somatostatin receptor scintigraphy for diagnosis and treatment of tumor patients. Eur J Clin Invest 27: 793-800, 1997.
167. 1-octreotide in 194 carcinoid patients: Vienna University experience, 1993 to 1998. J Clin Oncol 18: 1331-1336, 2000.
168. 99mTc-labeled vasoactive intestinal peptide analog for rapid localization of tumors in humans. J Nucl Med 41: 107-110, 2000.
169. 99mTc-VIP analog. J Nucl Med 45: 1381-1389, 2004.
170. 18F]fluoro-D-glucose in nude mice bearing breast cancer xenografts. Mol Imaging Biol 4: 369-379, 2002.
171. 1 receptors in human, rat, and guinea pig. J Pharm Exp Ther 301: 37-50, 2002.
172. Bhargava S, Licha K, Knaute T, Ebert B, Becker A, Grotzinger C, Hessenius C, Wiedenmann B, Schneider-Mergener J and Volkmer-Engert R: A complete substitutional analysis of VIP for better tumor imaging properties. J Mol Recog 15: 145-153, 2002.
173. Hruby VJ, Sharma SD, Toth K, Jaw JY, al-Obeidi F, Sawyer TK and Hadley ME: Design, synthesis, and conformation of superpotent and prolonged acting melanotropins. Ann NY Acad Sci 680: 51-63, 1993.
174. Siegrist W, Solca F, Stutz S, Giuffre L, Carrel S, Girard J and Eberle AN: Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells. Cancer Res 49: 6352-6358, 1989.
175. Tatro JB, Atkins M, Mier JW, Hardarson S, Wolfe H, Smith T, Entwistle ML and Reichlin S: Melanotropin receptors demonstrated in situ in human melanoma. J Clin Invest 85: 1825-1832, 1990.
176. Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB and Hadley ME: 4-Norleucine, 7-D-phenylalanine-alpha- melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci USA 77: 5754-5758, 1980.
177. Bard DR, Knight CG and Page-Thomas DP: A chelating derivative of alpha-melanocyte stimulating hormone as a potential imaging agent for malignant melanoma. Br J Cancer 62: 919-922, 1990.
178. Wraight EP, Bard DR, Maughan TS, Knight CG and Page-Thomas DP: The use of a chelating derivative of alpha melanocyte stimulating hormone for the clinical imaging of malignant melanoma. Br J Radiol 65 112-118, 1992.
179. Tatro JB and Reichlin S: Specific receptors for α-melanocyte-stimulating hormone are widely distributed in tissues of rodents. Endocrinol 121: 1900-1907, 1987.
180. Garg PK, Alston KL, Welsh PC and Zalutsky MR: Enhanced binding and inertness to dehalogenation of α-melanotropic peptides labeled using N-Succinimidyl 3-iodobenzoate. Bioconj Chem 7: 233-239, 1996.
181. Froidevaux S, Calame-Christe M, Tanner H, Sumanovski L and Eberle AN: A novel DOTA-α-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis. J Nucl Med 43: 1699-1706, 2002.
182. Froidevaux S, Calame-Christe M, Schuhmacher J, Tanner H, Saffrich R, Henze M and Eberle AN: A gallium-labeled DOTA-α-melanocyte-stimulating hormone peptide analog for PET imaging of melanoma metastases. J Nucl Med 45: 116-123, 2004.
183. Cody WL, Mahoney M, Knittel JJ, Hruby VJ, Castrucci AM and Hadley ME: Cyclic melanotropins. 9. 7-D-Phenylalanine analogues of the active-site sequence. J Med Chem 28: 583-588, 1985.
184. 99mtechnetium-labeled cyclic α-melanocyte-stimulating hormone peptide analogues. Cancer Res 60: 5649-5658, 2000.
185. Miao Y, Whitener D, Feng W, Owen NK, Chen J and Quinn TP: Evaluation of the human melanoma targeting properties of radiolabeled α-stimulating hormone peptide analogues. Bioconj Chem 14: 1177-1184, 2003.
186. 111In-labeled DOTA-conjugated rhenium-cyclized α-MSH analogues. J Med Chem 45: 3048-3056, 2002.